פראג'קט 200 וטרינרי إسرائيل - العبرية - Ministry of Health

פראג'קט 200 וטרינרי

abic veterinary products ltd - ferrous as dextran - תמיסה להזרקה - ferrous as dextran 200 mg/ml

וילאט 1000 إسرائيل - العبرية - Ministry of Health

וילאט 1000

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

וילאט 500 إسرائيل - العبرية - Ministry of Health

וילאט 500

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

סנדאימון תמיסה מרוכזת לאינפוזיה إسرائيل - العبرية - Ministry of Health

סנדאימון תמיסה מרוכזת לאינפוזיה

novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.

רבלימיד 5 מ"ג إسرائيل - العبرية - Ministry of Health

רבלימיד 5 מ"ג

neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 5 מג إسرائيل - العبرية - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.